Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

Hdl Handle:
http://hdl.handle.net/10147/324221
Title:
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe
Authors:
Frentz, Dineke; Van de Vijver, David AMC; Abecasis, Ana B; Albert, Jan; Hamouda, Osamah; Jørgensen, Louise B; Kücherer, Claudia; Struck, Daniel; Schmit, Jean-Claude; Vercauteren, Jurgen; Åsjö, Birgitta; Balotta, Claudia; Beshkov, Danail; Camacho, Ricardo J; Clotet, Bonaventura; Coughlan, Suzie; Griskevicius, Algirdas; Grossman, Zehava; Horban, Andrzej; Kolupajeva, Tatjana; Korn, Klaus; Kostrikis, Leondios G; Liitsola, Kirsi; Linka, Marek; Nielsen, Claus; Otelea, Dan; Paraskevis, Dimitrios; Paredes, Roger; Poljak, Mario; Puchhammer-Stöckl, Elisabeth; Sönnerborg, Anders; Stanekova, Danica; Stanojevic, Maja; Van Wijngaerden, Eric; Wensing, Annemarie MJ; Boucher, Charles AB; on behalf of the SPREAD Programme
Citation:
Frentz D. et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infectious Diseases. 2014 Jul 21;14(1):407
Issue Date:
21-Jul-2014
URI:
http://dx.doi.org/10.1186/1471-2334-14-407; http://hdl.handle.net/10147/324221
Abstract:
Abstract Background One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program. Methods Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy. Results The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained constant at 5%, a significant decline in protease inhibitors resistance mutations was observed, from 3.9% in 2002 to 1.6% in 2007 (p = 0.001). In contrast, resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) doubled from 2.0% in 2002 to 4.1% in 2007 (p = 0.004) with 58% of viral strains carrying a K103N mutation. Phylogenetic analysis showed that these temporal changes could not be explained by large clusters of TDRM. Conclusion During the years 2002 to 2007 transmitted resistance to NNRTI has doubled to 4% in Europe. The frequent use of NNRTI in first-line regimens and the clinical impact of NNRTI mutations warrants continued monitoring.
Language:
en
Keywords:
HIV INFECTION; COMMUNICABLE DISEASE

Full metadata record

DC FieldValue Language
dc.contributor.authorFrentz, Dinekeen_GB
dc.contributor.authorVan de Vijver, David AMCen_GB
dc.contributor.authorAbecasis, Ana Ben_GB
dc.contributor.authorAlbert, Janen_GB
dc.contributor.authorHamouda, Osamahen_GB
dc.contributor.authorJørgensen, Louise Ben_GB
dc.contributor.authorKücherer, Claudiaen_GB
dc.contributor.authorStruck, Danielen_GB
dc.contributor.authorSchmit, Jean-Claudeen_GB
dc.contributor.authorVercauteren, Jurgenen_GB
dc.contributor.authorÅsjö, Birgittaen_GB
dc.contributor.authorBalotta, Claudiaen_GB
dc.contributor.authorBeshkov, Danailen_GB
dc.contributor.authorCamacho, Ricardo Jen_GB
dc.contributor.authorClotet, Bonaventuraen_GB
dc.contributor.authorCoughlan, Suzieen_GB
dc.contributor.authorGriskevicius, Algirdasen_GB
dc.contributor.authorGrossman, Zehavaen_GB
dc.contributor.authorHorban, Andrzejen_GB
dc.contributor.authorKolupajeva, Tatjanaen_GB
dc.contributor.authorKorn, Klausen_GB
dc.contributor.authorKostrikis, Leondios Gen_GB
dc.contributor.authorLiitsola, Kirsien_GB
dc.contributor.authorLinka, Mareken_GB
dc.contributor.authorNielsen, Clausen_GB
dc.contributor.authorOtelea, Danen_GB
dc.contributor.authorParaskevis, Dimitriosen_GB
dc.contributor.authorParedes, Rogeren_GB
dc.contributor.authorPoljak, Marioen_GB
dc.contributor.authorPuchhammer-Stöckl, Elisabethen_GB
dc.contributor.authorSönnerborg, Andersen_GB
dc.contributor.authorStanekova, Danicaen_GB
dc.contributor.authorStanojevic, Majaen_GB
dc.contributor.authorVan Wijngaerden, Ericen_GB
dc.contributor.authorWensing, Annemarie MJen_GB
dc.contributor.authorBoucher, Charles ABen_GB
dc.contributor.authoron behalf of the SPREAD Programmeen_GB
dc.date.accessioned2014-08-05T11:43:44Z-
dc.date.available2014-08-05T11:43:44Z-
dc.date.issued2014-07-21-
dc.identifier.citationFrentz D. et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infectious Diseases. 2014 Jul 21;14(1):407en_GB
dc.identifier.urihttp://dx.doi.org/10.1186/1471-2334-14-407-
dc.identifier.urihttp://hdl.handle.net/10147/324221-
dc.description.abstractAbstract Background One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program. Methods Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy. Results The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained constant at 5%, a significant decline in protease inhibitors resistance mutations was observed, from 3.9% in 2002 to 1.6% in 2007 (p = 0.001). In contrast, resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) doubled from 2.0% in 2002 to 4.1% in 2007 (p = 0.004) with 58% of viral strains carrying a K103N mutation. Phylogenetic analysis showed that these temporal changes could not be explained by large clusters of TDRM. Conclusion During the years 2002 to 2007 transmitted resistance to NNRTI has doubled to 4% in Europe. The frequent use of NNRTI in first-line regimens and the clinical impact of NNRTI mutations warrants continued monitoring.-
dc.language.isoenen
dc.subjectHIV INFECTIONen_GB
dc.subjectCOMMUNICABLE DISEASEen_GB
dc.titleIncrease in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europeen_GB
dc.language.rfc3066en-
dc.rights.holderDineke Frentz et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2014-08-01T11:21:11Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.